The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2024 | A trial investigating enoxaparin vs placebo as thromboprophylaxis in hospitalized older patients
Gregoire Le Gal, MD, PhD, University Of Ottawa, Ottawa, Canada, discusses the findings of a study comparing enoxaparin to placebo for the prevention of symptomatic venous thromboembolism (VTE) in hospitalized older patients (NCT02379806). Prof. Le Gal outlines the study’s rationale, findings, and possible adjustments that should be made in future trials. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Inari, Sanofi.
